ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 393,76
0,18%
Dow Jones
42 392,27
-0,36%
DAX
20 024,66
0,58%
Brent Oil
75,855
0,00%
Bitcoin
96 896,52
0,00%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Viking Therapeutics Inc (VKTX) Cours

Viking Therapeutics Inc

Viking Therapeutics Inc (VKTX)

NASDAQ
41,12
0,88
(2,19%)
À la fermeture: 03 Janvier 10:00PM
Retardé de 15 minutes
41,30
0,18
( 0,44% )
Après les heures de négociation: 12:43AM
Retardé de 15 minutes

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Statistiques et détails clés

Dernier
41,30
Prix Achat
41,18
Prix Vente
41,50
Volume échangé
1 640 132
40,50 Fourchette du Jour 42,27
17,23 Plage de 52 semaines 99,3999
Cap du marché
4,602B
Clôture Veille
40,24
Ouverture
40,74
Dernière Transaction
10
@
41.19
Dernière heure de transaction
00:43:53
Volume financier
US$ 67 805 683
VWAP
41,3416
Volume moyen (3 m)
4 481 804
Actions en circulation
111 436 384
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-53,28
Bénéfice par action (BPA)
-0,77
Chiffre d'affairess
-
Bénéfice net
-85,9M

À propos de Viking Therapeutics Inc

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, ti... Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
www.vikingtherapeutics.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Viking Therapeutics Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker VKTX. Le dernier cours de clôture d'Viking Therapeutics était de US$40,24. Au cours de la dernière année, les actions de Viking Therapeutics ont été négociées dans une fourchette de prix de US$ 17,23 à US$ 99,3999.

Viking Therapeutics compte actuellement 111 436 384 actions en circulation. La capitalisation boursière d'Viking Therapeutics est de US$4,48 milliard. Viking Therapeutics a un ratio cours/bénéfice (ratio PE) de -53.28.

Flux d'options Viking Therapeutics (VKTX)

Voir le flux d'options complet

Flux global

Baissier

Prime nette

-1M

Calls / Puts

120,00%

Ach. / Vent.

44,00%

OTM / ITM

69,23%

Sweeps Ratio

0,00%

VKTX Dernières nouvelles

Plus de nouvelles

Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024

Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024 PR Newswire SAN DIEGO, Nov. 19, 2024 Oral Late Breaker...

19 Novembre 2024
PR Newswire (US)

Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024

Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024 PR Newswire SAN DIEGO, Nov. 12, 2024 Results...

12 Novembre 2024
PR Newswire (US)

Form 8-K - Current report

04 Novembre 2024
Edgar (US Regulatory)

Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024

Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024 PR Newswire SAN DIEGO, Nov. 4, 2024  Up to 6.8% Placebo-Adjusted Mean Weight Loss (8.2% from Baseline) After...

04 Novembre 2024
PR Newswire (US)

Viking Therapeutics to Participate at Upcoming Investor Conferences

Viking Therapeutics to Participate at Upcoming Investor Conferences PR Newswire SAN DIEGO, Oct. 31, 2024 SAN DIEGO, Oct. 31, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:...

31 Octobre 2024
PR Newswire (US)

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2024

Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2024 PR Newswire SAN DIEGO, Oct. 28, 2024 Results from VENTURE Phase 2 Study of...

28 Octobre 2024
PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities

26 Octobre 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

25 Octobre 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

23 Octobre 2024
Edgar (US Regulatory)

Form 8-K - Current report

23 Octobre 2024
Edgar (US Regulatory)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.64-1.5259895088241.9443.4839.0915248855940.81598893CS
4-9.57-18.812659720950.8752.5837.8359410543.24258997CS
12-20.71-33.397839058262.0181.729537.8448180457.59959333CS
26-12.71-23.532679133554.0181.729537.8389210058.97200795CS
5222.77122.88181327618.5399.399917.23437074561.69019846CS
15636.63784.3683083514.6799.39992.02294207436.60107901CS
26033.05400.6060606068.2599.39992.02221839430.26707099CS

VKTX - Frequently Asked Questions (FAQ)

What is the current Viking Therapeutics share price?
The current share price of Viking Therapeutics is US$ 41,30
How many Viking Therapeutics shares are in issue?
Viking Therapeutics has 111 436 384 shares in issue
What is the market cap of Viking Therapeutics?
The market capitalisation of Viking Therapeutics is USD 4,48B
What is the 1 year trading range for Viking Therapeutics share price?
Viking Therapeutics has traded in the range of US$ 17,23 to US$ 99,3999 during the past year
What is the PE ratio of Viking Therapeutics?
The price to earnings ratio of Viking Therapeutics is -53,28
What is the reporting currency for Viking Therapeutics?
Viking Therapeutics reports financial results in USD
What is the latest annual profit for Viking Therapeutics?
The latest annual profit of Viking Therapeutics is USD -85,9M
What is the registered address of Viking Therapeutics?
The registered address for Viking Therapeutics is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Viking Therapeutics website address?
The website address for Viking Therapeutics is www.vikingtherapeutics.com
Which industry sector does Viking Therapeutics operate in?
Viking Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
TGLTreasure Global Inc
US$ 0,3285
(73,35%)
17,54M
CHEKCheck Cap Ltd
US$ 1,81
(56,71%)
9,39M
MKZRMackenzie Realty Capital Inc
US$ 2,32
(28,18%)
27,54k
MGOLMGO Global Inc
US$ 0,7299
(23,50%)
5,94M
MFImF International Ltd
US$ 0,8779
(20,62%)
317,41k
MARXUMars Acquisition Corporation
US$ 2,85
(-25,00%)
1,05k
IDAIT Stamp Inc
US$ 0,515
(-24,60%)
1,14M
SKYESkye Bioscience Inc
US$ 2,40
(-15,79%)
733
HWHHWH International Inc
US$ 0,57
(-12,17%)
77,2k
ERNAEterna Therapeutics Inc
US$ 0,3302
(-10,51%)
168,48k
TGLTreasure Global Inc
US$ 0,3285
(73,35%)
17,54M
IVPInspire Veterinary Partners Inc
US$ 0,235
(13,97%)
13,12M
PLUGPlug Power Inc
US$ 2,34
(0,43%)
10,91M
CHEKCheck Cap Ltd
US$ 1,81
(56,71%)
9,39M
SVMHSRIVARU Holding Ltd
US$ 0,0588
(-2,00%)
8,92M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
VKTX
Viking Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés